AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9928755
Drug: Bendrofluazide 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendrofluazide 2.5 mg once daily
Trial: 6756418
Drug: Niludipine 20
RxNorm normalized name: nilvadipine
DrugBank: Nilvadipine (DB06712)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niludipine 20 mg, 4 times a day
Trial: 6756418
Drug: Niludipine 60
RxNorm normalized name: nilvadipine
DrugBank: Nilvadipine (DB06712)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niludipine 60 mg
Trial: 6756418
Drug: Niludipine 60
RxNorm normalized name: nilvadipine
DrugBank: Nilvadipine (DB06712)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niludipine 60 mg in normotensives
Trial: 6756418
Drug: Niludipine +
RxNorm normalized name: nilvadipine
DrugBank: Nilvadipine (DB06712)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niludipine + Propranolol 10 mg, 4 times a day
Trial: 6756418
Drug: Niludipine +
RxNorm normalized name: nilvadipine
DrugBank: Nilvadipine (DB06712)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niludipine + Propranolol + Penfluzide 2.5 mg a day
Trial: 22662740
Drug: Telephone-delivered cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-delivered cognitive-behavioral therapy (CBT)
Trial: 19654139
Drug: Bone-marrow-derived stem
RxNorm normalized name: Bone-marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone-marrow-derived stem cells (BMSC) administered by intracoronary infusion
Trial: 19654139
Drug: Bone-marrow-derived stem
RxNorm normalized name: Bone-marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone-marrow-derived stem cells (BMSC) delivered by intra-myocardial injection
Trial: 17617290
Drug: Generic terazosin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic terazosin (2 mg/d for 2 weeks, then adjusted to 1 mg/d or 4 mg/d)
Trial: 17617290
Drug: Branded terazosin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branded terazosin (2 mg/d for 2 weeks, then adjusted to 1 mg/d or 4 mg/d)
Trial: 14694168
Drug: Intravenous methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous methylprednisolone plus oral prednisone
Trial: 11576413
Drug: 0.1% mometasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% mometasone furoate ointment
Trial: 11576413
Drug: 0.005% fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.005% fluticasone proprionate ointment
Trial: 11576413
Drug: Wet wraps
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wet wraps with either ointment after 2 weeks
Trial: 2656860
Drug: Captopril 50
RxNorm normalized name: captopril 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 50 mg (11 patients) and 25 mg (1 patient) twice daily for 4 weeks
Trial: 19750263
Drug: Extra parenteral
RxNorm normalized name: Panadol Extra
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extra parenteral fluid therapy (group I)
Trial: 9307346
Drug: Intravenous ampicillin
RxNorm normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ampicillin (2-g dose every 6 hours) and erythromycin (250-mg dose every 6 hours) for 48 hours followed by oral amoxicillin (250-mg dose every 8 hours) and erythromycin base (333-mg dose every 8 hours) for 5 days
Trial: 9307346
Drug: Intravenous ampicillin
RxNorm normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ampicillin and erythromycin
Trial: 8103875
Drug: Intravenous streptokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous streptokinase (SK) 1.5 MU
Trial: 3734034
Drug: RU 486
RxNorm normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RU 486 (400 mg acute administration)
Trial: 3734034
Drug: RU 486
RxNorm normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RU 486 (400 mg daily for 3 days)
Trial: 28695791
Drug: L+Z supplementation
RxNorm normalized name: Z-160
DrugBank: Z-160 (DB12743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L+Z supplementation (12 mg/daily)
Trial: 22507791
Drug: New agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New agents targeting different pathways such as lenalidomide
Trial: 22507791
Drug: New monoclonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New monoclonal antibodies
Trial: 22507791
Drug: Bruton’s tyrosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bruton’s tyrosine kinase inhibitor
Trial: 12809395
Drug: Chest tubes
RxNorm normalized name: Kids-Eeze Chest Relief
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chest tubes removed at the second postoperative day when drainage output declined to less than 50 mL in a five-hour period.
Trial: 31907007
Drug: Therapeutic drug
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic drug monitoring (TDM) of infliximab
Trial: 31907007
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with infliximab without knowledge of drug levels or ADAb status
Trial: 23770919
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection with 400 μg cobalamin
Trial: 21386706
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment with amlodipine/valsartan (10/320 mg)
Trial: 21386706
Drug: Moderate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate treatment with amlodipine/valsartan (5/160 mg)
Trial: 21386706
Drug: Moderate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate treatment
Trial: 17921831
Drug: Spironolactone (12.5-50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (12.5-50 mg/day for 3 months)
Trial: 15156996
Drug: IN‐BP (intranasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IN‐BP (intranasal vaccine without canine‐adenovirus type 2)
Trial: 15156996
Drug: IN‐BPA (intranasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IN‐BPA (intranasal vaccine with canine‐adenovirus type 2)
Trial: 12490862
Drug: OC 3
RxNorm normalized name: maraviroc 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OC 3 g per day
Trial: 12490862
Drug: OC 3
RxNorm normalized name: maraviroc 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OC 3 g + VD 1 mg per day
Trial: 10321142
Drug: Fixed treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed treatments
Trial: 10321142
Drug: Functional treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional treatments
Trial: 7840077
Drug: Oral-glucose-tolerance test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral-glucose-tolerance test (OGTT) on day 14
Trial: 7840077
Drug: Oral-sucrose-tolerance test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral-sucrose-tolerance test (OSTT) on day 14
Trial: 20656
Drug: Benorylate tablets
RxNorm normalized name: benorilate Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benorylate tablets (4.5 g daily dosage)
Trial: 26193987
Drug: Gravity-fed infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gravity-fed infusion (GFI)
Trial: 26193987
Drug: Infusion pump
RxNorm normalized name: Infusion Pump 50cc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion pump (IP)
Trial: 26193987
Drug: Gravity-fed infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gravity-fed infusion with post-administration rinsing (PAR)
Trial: 21862934
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of plasmapheresis and immunosuppression
Trial: 21862934
Drug: Steroids and
RxNorm normalized name: Corticosteroids and mydriatics in combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroids and cytotoxic agents
Trial: 21862934
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of plasmapheresis plus corticosteroids and cyclophosphamide
Trial: 17320090
Drug: Chokeberry flavonoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chokeberry flavonoid extract (3 x 85 mg/day)
Trial: 15025841
Drug: Ximelagatran dissolved
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ximelagatran dissolved in water and administered via nasogastric tube
Trial: 12575392
Drug: Recombinant roasted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant roasted licorice decoction (RRLD) plus low-dose glucocorticoids (GC)
Trial: 12575392
Drug: Normal dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal dosage of glucocorticoids (GC)
Trial: 7874375
Drug: benazepril 5
RxNorm normalized name: benazepril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: benazepril 5 mg + hydrochlorothiazide 6.25 mg
Trial: 7874375
Drug: benazepril 10
RxNorm normalized name: benazepril 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: benazepril 10 mg + hydrochlorothiazide 12.5 mg
Trial: 3044673
Drug: Hexopal (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hexopal (4 g/day)
Trial: 21745726
Drug: Anodal transcranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anodal transcranial direct current stimulation (tDCS) to the left dorsolateral prefrontal cortex, administered for 20 min at an intensity of 2.0 mA during 150 trials of a probabilistic association learning test.
Trial: 24388379
Drug: Ketotifen 0.025%
RxNorm normalized name: KETOTIFEN 0.025% OPH SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketotifen 0.025% ophthalmic solution
Trial: 1468429
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg loracarbef in fasting state
Trial: 1468429
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg loracarbef following a standard breakfast
Trial: 1468429
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg loracarbef with 200 mg acetylcysteine
Trial: 6385931
Drug: 1% topical
RxNorm normalized name: SSD 1% Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% topical indomethacin
Trial: 6385931
Drug: 0.1% topical
RxNorm normalized name: Halog 0.1% Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% topical dexamethasone sodium phosphate
Trial: 6385931
Drug: Both topical
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both topical indomethacin and dexamethasone
Trial: 30074109
Drug: LED-LLLT (830/590
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LED-LLLT (830/590 nm) applied after fractional CO2 laser treatment on one side of the face
Trial: 24650022
Drug: Ropivacaine (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine (75 mL, 150 mg)
Trial: 17975791
Drug: 14 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 14 weeks of treatment with pegylated interferon alpha-2b (1.5 microg/kg) subcutaneously weekly and ribavirin (800-1400 mg) orally daily
Trial: 17975791
Drug: 24 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 24 weeks of treatment with pegylated interferon alpha-2b (1.5 microg/kg) subcutaneously weekly and ribavirin (800-1400 mg) orally daily
Trial: 9135733
Drug: Cationic liposomes
RxNorm normalized name: Potassium cation
DrugBank: Potassium cation (DB01345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cationic liposomes with plasmid containing human CFTR cDNA (administered to 8 patients)
Trial: 3656112
Drug: Benzphetamine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzphetamine (25 and 50 mg)
Trial: 3656112
Drug: Phenmetrazine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenmetrazine (25 and 50 mg)
Trial: 3656112
Drug: Mazindol (0.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mazindol (0.5, 1.0 and 2.0 mg)
Trial: 3656112
Drug: Phenylpropanolamine (12.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylpropanolamine (12.5, 25 and 50 mg)
Trial: 31020673
Drug: Susceptibility-guided therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Susceptibility-guided therapy (esomeprazole 20 mg, amoxicillin 1 g b.d., clarithromycin 500 mg, metronidazole 400 mg b.d., or levofloxacin 500 mg daily for susceptible infections; bismuth 220 mg b.d. and metronidazole 400 mg q.d.s. for triple-resistant infections)
Trial: 31020673
Drug: Empiric therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empiric therapy (esomeprazole 20 mg, bismuth 220 mg b.d., amoxicillin 1 g, metronidazole 400 mg t.d.s.)
Trial: 16595220
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (triptorelin)
Trial: 12671890
Drug: VPA‐985 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VPA‐985 100 mg/day
Trial: 12671890
Drug: VPA‐985 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VPA‐985 200 mg/day
Trial: 11022985
Drug: Budesonide 800
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide 800 microg daily
Trial: 11022985
Drug: Budesonide 1600
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide 1600 microg daily
Trial: 1584644
Drug: Functional orthotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional orthotic therapy (CALIGAMED splint)
Trial: 29343449
Drug: 1.5g TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5g TXA in 100mL normal saline solution (IA group, n=58)
Trial: 29343449
Drug: 1.5g TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5g TXA in 100mL normal saline solution (IA group)
Trial: 20495498
Drug: Intravascular radiation
RxNorm normalized name: acellular tissue engineered vessel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravascular radiation therapy (IVRT) using Re-188 filled balloon, 18 Gy dose at 0.5 mm depth, after successful coronary angioplasty
Trial: 17309153
Drug: Chemotherapy (CT)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (CT) - 4 patients, 4-6 cycles
Trial: 17309153
Drug: Chemotherapy/Radiotherapy (CT/RT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy/Radiotherapy (CT/RT) - 8 patients, 1-2 cycles of CT before RT and 4 cycles after RT
Trial: 17309153
Drug: Radiotherapy (RT)
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiotherapy (RT) - 3 patients, external beam radiotherapy (EBRT), total dose 45 Gy, 24 fractions
Trial: 17309153
Drug: Overall survival
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall survival (OS) across all therapy groups
Trial: 9180113
Drug: Ticlopidine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticlopidine plus aspirin
Trial: 1336898
Drug: 50-mg doses
RxNorm normalized name: docusate sodium 50 MG [Doculase]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50-mg doses of oral etoposide given twice daily for 14 days every 3 weeks
Trial: 1336898
Drug: 50-mg doses
RxNorm normalized name: docusate sodium 50 MG [Doculase]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50-mg doses of oral etoposide given once daily for 21 days every 4 weeks
Trial: 1336898
Drug: 50-mg doses
RxNorm normalized name: docusate sodium 50 MG [Doculase]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50-mg doses of oral etoposide given twice daily for 10 days every 3 weeks
Trial: 3994433
Drug: Clindamycin 600
RxNorm normalized name: clindamycin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin 600 mg every 6 hours and Tobramycin 1.2 mg/kg every 6 hours (CT)
Trial: 26861939
Drug: Evening dosing
RxNorm normalized name: Evening Dosing 24 HR Jornay 60 MG Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evening dosing of antihypertensive medication
Trial: 26861939
Drug: Morning dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning dosing of antihypertensive medication
Trial: 28925801
Drug: MF59-adjuvanted trivalent
RxNorm normalized name: Influenza, adjuvanted, trivalent, PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF59-adjuvanted trivalent influenza vaccine FLUAD® (aTIV)
Trial: 28925801
Drug: Non-adjuvanted trivalent
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-adjuvanted trivalent influenza vaccine (TIV)
Trial: 27269416
Drug: Povidone Iodine
RxNorm normalized name: POVIDONE IODINE
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Povidone Iodine (PVI) solution used to cleanse skin around wounds
Trial: 15700313
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg fenretinide daily for 1 year
Trial: 12825106
Drug: Sildenafil 50
RxNorm normalized name: sildenafil 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 50 mg (adjustable to 100 or 25 mg)
Trial: 1819547
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH), 0.1 U/kg daily (group A)
Trial: 1819547
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH), 0.1 U/kg daily plus oxandrolone, 0.06 mg/kg (group B)
Trial: 6756151
Drug: High-dose estrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose estrogen (17 beta-estradiol and estriol with norethisterone acetate)
Trial: 6756151
Drug: Medium-dose estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-dose estrogen (17 beta-estradiol and estriol with norethisterone acetate)
Trial: 6756151
Drug: Low-dose estrogen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose estrogen (17 beta-estradiol and estriol with norethisterone acetate)
Trial: 27213635
Drug: Blended CBT
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blended CBT (9 face-to-face sessions, supplemented with digital support via tablet and 3 e-mail contacts)
Trial: 27213635
Drug: Regular CBT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular CBT (12 weekly sessions)
Trial: 17639748
Drug: Local periodontal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local periodontal therapy
Trial: 15642809
Drug: Topical 0.5%
RxNorm normalized name: phenol topical 0.5% topical spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.5% timolol treatment for 3 years
Trial: 12372573
Drug: Intravenous amiodarone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous amiodarone (150 mg bolus)
Trial: 12372573
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine (100 mg bolus)
Trial: 9987702
Drug: Acetaminophen (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (4 g/d) for 1 day
Trial: 9987702
Drug: Acetaminophen (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (4 g/d) for 2 weeks
Trial: 7582676
Drug: Valine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valine (30 g)
Trial: 31640977
Drug: Daptomycin plus
RxNorm normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daptomycin plus ceftaroline (combination therapy)
Trial: 31640977
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care monotherapy (control)
Trial: 25481378
Drug: As-needed budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: As-needed budesonide and formoterol therapy
Trial: 25481378
Drug: Regular budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Regular budesonide and formoterol therapy
Trial: 23675619
Drug: Pulsating electromagnetic
RxNorm normalized name: ABG Pulsator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsating electromagnetic field (PEMF) therapy (15 min exposure, low-frequency PEMF, 5 days/week for 12 weeks)
Trial: 21843027
Drug: Gluma Desensitizer
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gluma Desensitizer with G-Cem
Trial: 19526754
Drug: Shenfu Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenfu Injection (SFI) given once a day at a dose of 40 mL after dilution for one week.
Trial: 19526754
Drug: Western medical
RxNorm normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medical conventional treatment (Control group).
Trial: 15476445
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment (Genotropin) for six months followed by 12 months of GH for all participants